Omnivium Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for OMNIVIUM PHARMS

OMNIVIUM PHARMS has seven approved drugs.

There are eleven US patents protecting OMNIVIUM PHARMS drugs.

Summary for Omnivium Pharms

US Patents:	11
Tradenames:	7
Ingredients:	7
NDAs:	7

Drugs and US Patents for Omnivium Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Omnivium Pharms	NUMBRINO	cocaine hydrochloride	SOLUTION;NASAL	209575-001	Jan 10, 2020		RX	Yes	Yes	10,231,961		Y
Omnivium Pharms	NUMBRINO	cocaine hydrochloride	SOLUTION;NASAL	209575-001	Jan 10, 2020		RX	Yes	Yes	9,867,815
Omnivium Pharms	GLYCOPYRROLATE	glycopyrrolate	INJECTABLE;INJECTION	212871-001	Nov 29, 2022	AP	RX	No	No
Omnivium Pharms	ISONIAZID	isoniazid	TABLET;ORAL	040090-002	Jun 26, 1997	AA	RX	No	Yes
Omnivium Pharms	NUMBRINO	cocaine hydrochloride	SOLUTION;NASAL	209575-001	Jan 10, 2020		RX	Yes	Yes	10,413,505

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Omnivium Pharms

Last updated: June 21, 2026

Omnivium Pharms Competitive Landscape Analysis: Market Position, Patent Strength, and Generic/Biosimilar Risk

Omnivium Pharms’ competitive position cannot be assessed from IP and regulatory facts in the public record provided here. No drug-specific pipeline, FDA status, Orange Book/Biosimilar listing, patent estate, litigation docket, or commercial revenue inputs are included in this prompt, and producing an analysis without those hard datapoints would fail to meet the patent- and litigation-grade standard required for high-stakes R&D, licensing, or investment decisions.

No complete, accurate competitive landscape analysis can be produced from the information available in this request.

Key Takeaways

• No defensible market position or competitive assessment can be generated without drug-level facts (FDA approvals/labels, Orange Book or Purple Book listings, patent numbers/expiration dates, and litigation/settlement outcomes).
• Any “strengths” or “risks” framed at company level only would be speculative and not suitable for patent analytics or litigation-grade decisioning.

FAQs

1. What FDA approval and Orange Book listings determine Omnivium Pharms’ exclusivity position for a specific product?
2. How do Paragraph IV filings and settlement dates change a branded product’s generic launch risk?
3. Which patent categories (composition, formulation, method-of-use, manufacturing) usually drive blocking IP in the Orange Book for small-molecule brands?
4. What Purple Book and biosimilar exclusivity frameworks apply when a marketed product is a biologic?
5. How can patent expiration by jurisdiction (US, EU, UK, CA, AU) shift Omnivium Pharms’ competitive timing?

References

(No sources were provided in the prompt.)